Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated ...
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving ...
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record levelsHOUSTON, TX, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This ...
The Canadian Press on MSN
What is 'food noise' and why are we hearing about it amid the rise of GLP-1 meds?
Before Brenda Rogers started taking Ozempic in the spring of 2023, she didn't realize how much "food noise" was sapping her ...
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings ...
A new study led by researchers at the University of Oxford, which reviewed 37 existing weight loss medication studies ...
Berberine, Zinc, and Quercetin in the Context of Rising Consumer Interest in Natural GLP-1 Support and Non-Prescription ...
This rate of weight regain is significantly faster than that seen in those who have lost weight by changing other lifestyle ...
23h
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading Into 2026NEWARK, DE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ...
Novo Nordisk (NVO) downgraded to Hold after FDA GLP-1 actions and 2026 patent cliffs threaten Wegovy supply and growth. See ...
While many have found success with medication, they are not a cure-all and experts caution they are not without risk.
GLP-1 meds are are highly effective at treating diabetes, obesity and other conditions. But when people stop using them, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback